表紙
市場調査レポート

心筋梗塞:パイプライン分析

Myocardial Infarction - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229746
出版日 ページ情報 英文 358 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
心筋梗塞:パイプライン分析 Myocardial Infarction - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 358 Pages
概要

心筋梗塞(または心臓虚血)は、心筋への血流・酸素供給が不足した際に生じます。主な徴候・症状として、胸痛(特に人体の左側(狭心症))をはじめ、頚部・顎の痛み、肩・腕の痛み、冷や汗、息切れ、吐き気・嘔吐などが挙げられます。また、冠動脈疾患(アテローム硬化症)や血栓、冠血管攣縮、その他の重病が原因で発症することがあります。発症リスクの増大要因として、喫煙や糖尿病、高血圧、高コレステロール血症(高トリグリセリド血症)、運動不足、肥満、家族歴などが考えられています。

当レポートでは、世界各国での心筋梗塞治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

心筋梗塞の概要

治療薬の開発

  • 心筋梗塞向けパイプライン製品:概要
  • 心筋梗塞向けパイプライン製品:比較分析

各企業で開発中の心筋梗塞治療薬

大学/研究機関で研究中の心筋梗塞治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

心筋梗塞治療薬:開発中の製品の一覧(企業別)

心筋梗塞治療薬:研究中の製品の一覧(大学/研究機関別)

心筋梗塞治療薬の開発に従事している企業

  • Amarantus Bioscience Holdings, Inc.
  • Angion Biomedica Corp.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bharat Biotech International Limited
  • BioCardia, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • CellProthera
  • Celyad SA
  • Compugen Ltd.
  • CSL Limited
  • Cynata Therapeutics Limited
  • FibroGen, Inc.
  • Hemostemix Ltd
  • Human Stem Cells Institute
  • HUYA Bioscience International, LLC
  • Immune Pharmaceuticals Inc.
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Lee's Pharmaceutical Holdings Limited
  • LegoChem Biosciences, Inc
  • LG Life Science LTD.
  • Medestea Research & Production S.p.A.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • Moderna Therapeutics, Inc.
  • MorphoSys AG
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novartis AG
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • Polyphor Ltd.
  • Primary Peptides, Inc.
  • Quantum Genomics SA
  • Quark Pharmaceuticals, Inc.
  • Recardio GmbH
  • Serodus ASA
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • The International Biotechnology Center (IBC) Generium
  • TiGenix NV
  • Vicore Pharma AB
  • XBiotech USA, Inc.
  • Yuyu Pharma, Inc.
  • Zydus Cadila Healthcare Limited

心筋梗塞:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (sacubitril + valsartan)
  • AB-002
  • ACP-01
  • Alda-1
  • アルテプラーゼ(血栓溶解薬)のバイオシミラー
  • AMRS-001
  • ANG-4011
  • 心筋梗塞向けmiR-92阻害アンチセンスRNAiオリゴヌクレオチド
  • AP-102
  • APO-1
  • balixafortide
  • リウマチ性関節炎・急性心筋梗塞・炎症性疾患向けバイオシミラー 3
  • BIS-5409
  • bococizumab
  • burixafor
  • C-21
  • C3BSGQR-3
  • C3BSGQR-4
  • CAP-1001
  • CAP-1002
  • cenderitide
  • CGEN-856S
  • CIGB-500
  • CM-1
  • Cryocell
  • CSL-112
  • CTX-101
  • cyclosporine
  • 循環器疾患向けAlpha Myosin阻害薬
  • 虚血性脳卒中・心筋梗塞向けSIRT2阻害薬
  • dutogliptin tartrate
  • elamipretide
  • 心筋梗塞向けエフリンA-1
  • F-573
  • FG-6874
  • Gemacell
  • 急性心筋梗塞向け遺伝子療法
  • HBI-3802
  • HYPER-IL-6
  • ICG-001
  • IS-20
  • JI-38
  • JVS-100
  • JVS-200
  • KR-33028
  • LC-280126
  • LWnt-3a
  • Lysimab
  • MGN-1374
  • MGN-6114
  • MIF-2
  • MIF-20
  • 心筋梗塞・アテローム性動脈硬化症向けIL-1a阻害モノクローナル抗体
  • 心筋梗塞向けマンノース受容体標的モノクローナル抗体複合体
  • MPC-150IM
  • MPC-25IC
  • Neu-2000
  • NP-202
  • NVP-019
  • NVX-308
  • NWL-53
  • 腫瘍学・心臓血管向けオリゴヌクレオチド
  • 循環器疾患・腎疾患 向けオリゴヌクレオチド
  • OMS-721
  • OPC-28326
  • 循環器疾患・代謝障害・勃起障害向けMas関連Gタンパク質共役受容体活性ペプチド
  • 糖尿病・心不全向けアペリン受容体作動ペプチド
  • PF-05285401
  • 急性心筋梗塞向けポリグラクチン 370
  • PP-001
  • 心筋梗塞・重症肢虚血向けLRP5/LRP6作動タンパク
  • ProtheraCytes
  • QGC-101
  • QPCP-1
  • RBB-001
  • 循環器疾患向け組換タンパク
  • 心筋梗塞向け組換タンパク質
  • 心筋梗塞向けIGF-1R作動組換タンパク
  • 組換プロウロキナーゼ
  • remestemcel-L
  • rivaroxaban
  • 心筋梗塞向けRNAiオリゴヌクレオチド
  • salicylamine
  • SER-130
  • 心筋梗塞向け小分子
  • 再かん流傷害・心臓まひ向け小分子
  • CAHD・脳卒中向け血液因子XIa阻害剤
  • 心筋梗塞・炎症性疾患向け小分子
  • 喘息・心筋梗塞向けアデノシンA2B受容体拮抗薬
  • 向け阻害剤 BAX 心筋梗塞向け
  • 向け阻害剤 MMP 心筋梗塞向け
  • 免疫学・腫瘍学・循環器疾患・代謝障害向けPARP阻害剤
  • 循環器疾患向けPDE5阻害剤
  • 酸化的ストレス関連疾患向け遊離基除去小分子
  • 急性心筋梗塞向け幹細胞療法
  • 循環器疾患向け幹細胞療法
  • 循環器疾患・中枢神経障害・代謝障害・呼吸器疾患・炎症性疾患・毒物学向け幹細胞療法
  • 循環器疾患向け幹細胞療法
  • 心筋梗塞・心不全向け幹細胞療法
  • Stempeucel
  • 循環器疾患向けエリスロポエチン(赤血球生成促進因子)受容体活性合成ペプチド
  • TF-0023
  • THR-100
  • ticagrelor
  • TZ-101
  • VN-100
  • ZK-001

心筋梗塞治療薬:パイプライン製品の最新動向

心筋梗塞治療薬:開発が休止状態の製品

心筋梗塞治療薬:開発が中止された製品

心筋梗塞関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7694IDB

Summary

Global Markets Direct's, 'Myocardial Infarction - Pipeline Review, H1 2016', provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
  • The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Infarction Overview
  • Therapeutics Development
    • Pipeline Products for Myocardial Infarction - Overview
    • Pipeline Products for Myocardial Infarction - Comparative Analysis
  • Myocardial Infarction - Therapeutics under Development by Companies
  • Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes
  • Myocardial Infarction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Myocardial Infarction - Products under Development by Companies
  • Myocardial Infarction - Products under Investigation by Universities/Institutes
  • Myocardial Infarction - Companies Involved in Therapeutics Development
    • Amarantus Bioscience Holdings, Inc.
    • Angion Biomedica Corp.
    • Asterias Biotherapeutics, Inc.
    • AstraZeneca Plc
    • Athersys, Inc.
    • Bayer AG
    • Bharat Biotech International Limited
    • BioCardia, Inc.
    • Biscayne Pharmaceuticals, Inc.
    • Capricor Therapeutics, Inc.
    • CellProthera
    • Celyad SA
    • Compugen Ltd.
    • CSL Limited
    • Cynata Therapeutics Limited
    • FibroGen, Inc.
    • Hemostemix Ltd
    • Human Stem Cells Institute
    • HUYA Bioscience International, LLC
    • Immune Pharmaceuticals Inc.
    • Juventas Therapeutics, Inc.
    • Laboratoires Pierre Fabre SA
    • Lee's Pharmaceutical Holdings Limited
    • LegoChem Biosciences, Inc
    • LG Life Science LTD.
    • Medestea Research & Production S.p.A.
    • Mesoblast Limited
    • miRagen Therapeutics, Inc.
    • Moderna Therapeutics, Inc.
    • MorphoSys AG
    • NeuroVive Pharmaceutical AB
    • New World Laboratories, Inc.
    • Novartis AG
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Polyphor Ltd.
    • Primary Peptides, Inc.
    • Quantum Genomics SA
    • Quark Pharmaceuticals, Inc.
    • Recardio GmbH
    • Serodus ASA
    • Silver Creek Pharmaceuticals, Inc.
    • Stealth BioTherapeutics Inc.
    • Stemedica Cell Technologies, Inc.
    • Stempeutics Research Private Limited
    • TaiGen Biotechnology Co., Ltd.
    • Targazyme, Inc.
    • The International Biotechnology Center (IBC) Generium
    • TiGenix NV
    • Vicore Pharma AB
    • XBiotech USA, Inc.
    • Yuyu Pharma, Inc.
    • Zydus Cadila Healthcare Limited
  • Myocardial Infarction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sacubitril + valsartan) - Drug Profile
    • AB-002 - Drug Profile
    • ACP-01 - Drug Profile
    • Alda-1 - Drug Profile
    • alteplase biosimilar - Drug Profile
    • AMRS-001 - Drug Profile
    • ANG-4011 - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit miR-92 for Myocardial Infarction - Drug Profile
    • AP-102 - Drug Profile
    • APO-1 - Drug Profile
    • balixafortide - Drug Profile
    • Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation - Drug Profile
    • BIS-5409 - Drug Profile
    • bococizumab - Drug Profile
    • burixafor - Drug Profile
    • C-21 - Drug Profile
    • C3BSGQR-3 - Drug Profile
    • C3BSGQR-4 - Drug Profile
    • CAP-1001 - Drug Profile
    • CAP-1002 - Drug Profile
    • cenderitide - Drug Profile
    • CGEN-856S - Drug Profile
    • CIGB-500 - Drug Profile
    • CM-1 - Drug Profile
    • Cryocell - Drug Profile
    • CSL-112 - Drug Profile
    • CTX-101 - Drug Profile
    • cyclosporine - Drug Profile
    • Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile
    • Drugs to Inhibit SIRT2 for Ischemic Stroke and Myocardial Infarction - Drug Profile
    • dutogliptin tartrate - Drug Profile
    • elamipretide - Drug Profile
    • Ephrin A-1 for Myocardial Infarction - Drug Profile
    • F-573 - Drug Profile
    • FG-6874 - Drug Profile
    • Gemacell - Drug Profile
    • Gene Therapy for Acute Myocardial Infarction - Drug Profile
    • HBI-3802 - Drug Profile
    • HYPER-IL-6 - Drug Profile
    • ICG-001 - Drug Profile
    • IS-20 - Drug Profile
    • JI-38 - Drug Profile
    • JVS-100 - Drug Profile
    • JVS-200 - Drug Profile
    • KR-33028 - Drug Profile
    • LC-280126 - Drug Profile
    • LWnt-3a - Drug Profile
    • Lysimab - Drug Profile
    • MGN-1374 - Drug Profile
    • MGN-6114 - Drug Profile
    • MIF-2 - Drug Profile
    • MIF-20 - Drug Profile
    • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
    • Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile
    • MPC-150IM - Drug Profile
    • MPC-25IC - Drug Profile
    • Neu-2000 - Drug Profile
    • NP-202 - Drug Profile
    • NVP-019 - Drug Profile
    • NVX-308 - Drug Profile
    • NWL-53 - Drug Profile
    • Oligonucleotide for Oncology and Cardiovascular - Drug Profile
    • Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile
    • OMS-721 - Drug Profile
    • OPC-28326 - Drug Profile
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
    • Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile
    • PF-05285401 - Drug Profile
    • Polyglactin 370 for Acute Myocardial Infarction - Drug Profile
    • PP-001 - Drug Profile
    • Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile
    • ProtheraCytes - Drug Profile
    • QGC-101 - Drug Profile
    • QPCP-1 - Drug Profile
    • RBB-001 - Drug Profile
    • Recombinant Protein for Cardiovascular Diseases - Drug Profile
    • Recombinant Protein for Myocardial Infarction - Drug Profile
    • Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile
    • Recombinant Prourokinase - Drug Profile
    • remestemcel-L - Drug Profile
    • rivaroxaban - Drug Profile
    • RNAi Oligonucleotide for Myocardial Infarction - Drug Profile
    • salicylamine - Drug Profile
    • SER-130 - Drug Profile
    • Small Molecule for Myocardial Infarction - Drug Profile
    • Small Molecule for Reperfusion Injury and Heart Attack - Drug Profile
    • Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
    • Small Molecules for Myocardial Infarction and Inflammation - Drug Profile
    • Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile
    • Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile
    • Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile
    • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
    • Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
    • Stem Cell Therapy for Acute Myocardial Infarction - Drug Profile
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
    • Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile
    • Stempeucel - Drug Profile
    • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
    • TF-0023 - Drug Profile
    • THR-100 - Drug Profile
    • ticagrelor - Drug Profile
    • TZ-101 - Drug Profile
    • VN-100 - Drug Profile
    • ZK-001 - Drug Profile
  • Myocardial Infarction - Recent Pipeline Updates
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Infarction, H1 2016
  • Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2016
  • Myocardial Infarction - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2016
  • Myocardial Infarction - Pipeline by Athersys, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Bayer AG, H1 2016
  • Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2016
  • Myocardial Infarction - Pipeline by BioCardia, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H1 2016
  • Myocardial Infarction - Pipeline by CellProthera, H1 2016
  • Myocardial Infarction - Pipeline by Celyad SA, H1 2016
  • Myocardial Infarction - Pipeline by Compugen Ltd., H1 2016
  • Myocardial Infarction - Pipeline by CSL Limited, H1 2016
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2016
  • Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2016
  • Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2016
  • Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H1 2016
  • Myocardial Infarction - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Myocardial Infarction - Pipeline by LG Life Science LTD., H1 2016
  • Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2016
  • Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Moderna Therapeutics, Inc., H1 2016
  • Myocardial Infarction - Pipeline by MorphoSys AG, H1 2016
  • Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H1 2016
  • Myocardial Infarction - Pipeline by New World Laboratories, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Novartis AG, H1 2016
  • Myocardial Infarction - Pipeline by Omeros Corporation, H1 2016
  • Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Myocardial Infarction - Pipeline by Pfizer Inc., H1 2016
  • Myocardial Infarction - Pipeline by Polyphor Ltd., H1 2016
  • Myocardial Infarction - Pipeline by Primary Peptides, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Quantum Genomics SA, H1 2016
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Recardio GmbH, H1 2016
  • Myocardial Infarction - Pipeline by Serodus ASA, H1 2016
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Stealth BioTherapeutics Inc., H1 2016
  • Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2016
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016
  • Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2016
  • Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Myocardial Infarction - Pipeline by TiGenix NV, H1 2016
  • Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2016
  • Myocardial Infarction - Pipeline by XBiotech USA, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H1 2016
  • Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2016
  • Myocardial Infarction - Dormant Projects, H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..1), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..2), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..3), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..4), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..5), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..6), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..7), H1 2016
  • Myocardial Infarction - Dormant Projects (Contd..8), H1 2016
  • Myocardial Infarction - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Myocardial Infarction, H1 2016
  • Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top